Drawing for EMVOKIR

USPTO serial 79362008

EMVOKIR

Reviewed by CopyMark Law Group

Reg. 7220761Status 700Registered
Filing date
Status date
Registration date
Nov 21, 2023
Examiner
SMITH, BRIDGETT G
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with EMVOKIR?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the prevention and treatment of diseases and disorders of the alimentary tract and metabolism, and of the blood and blood forming organs; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the cardiovascular system, musculoskeletal system, central nervous system, peripheral nervous system, genitourinary system and respiratory system; pharmaceutical preparations for the prevention and treatment of dermatological diseases and disorders, damaged skin and tissues; pharmaceutical preparations for the prevention and treatment of inflammation and inflammatory diseases and disorders; pharmaceutical preparations for the prevention and treatment of ophthalmological diseases and disorders; pharmaceutical preparations for the treatment and prevention of hormonal diseases and disorders; pharmaceutical preparations for the treatment and prevention of infectious diseases and disorders and viral infections; pharmaceutical preparations for the prevention and treatment of oncological and auto-immune diseases and disorders; pharmaceutical preparations, namely, cell-based immune therapeutics for treatment of cancer, for treatment of immunological diseases, and treatment of infectious diseasesACTIVE

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 21, 2024CCONCOUNTERCLAIM OPP. NO. 999999
Jan 12, 2024GPNXNOTIFICATION PROCESSED BY IB
Dec 22, 2023FICSFINAL DISPOSITION NOTICE SENT TO IB
Dec 22, 2023FIMPFINAL DISPOSITION PROCESSED
Dec 21, 2023GPARGRANT OF PROTECTION CREATED, TO BE SENT TO IB
Nov 21, 2023R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 18, 2023GPNXNOTIFICATION PROCESSED BY IB
Sep 5, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 30, 2023OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Aug 30, 2023OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Aug 16, 2023NPUBNOTICE OF PUBLICATION
Jul 30, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Jul 30, 2023DOCKASSIGNED TO EXAMINER
Feb 18, 2023MAFRAPPLICATION FILING RECEIPT MAILED
Feb 14, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 13, 2023LIMILIMITATION FROM ORIGINAL APPLICATION ENTERED
Feb 9, 2023REPRSN ASSIGNED FOR SECT 66A APPL FROM IB

Frequently asked questions

Related guidance